Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes: A Randomized Clinical Trial
Влияние терапии инсулиновой помпой с датчиком и автоматической приостановкой подачи инсулина по низкому уровню глюкозы по сравнению со стандартной терапией инсулиновой помпой на гипогликемию у пациентов с сахарным диабетом 1 типа
2013-09-24
SCID: 54.1/tkua4xgz
Discuss with AI
automated low-glucose insulin suspensionhypoglycemic clampsensor-augmented insulin pumpsevere and moderate hypoglycemiatype 1 diabetes
Figures from the paper
Abstract (AI)
IMPORTANCE: Hypoglycemia is a critical obstacle to the care of patients with type 1 diabetes. Sensor-augmented insulin pump with automated low-glucose insulin suspension has the potential to reduce the incidence of major hypoglycemic events. OBJECTIVE: To determine the incidence of severe and moderate hypoglycemia with sensor-augmented pump with low-glucose suspension compared with standard insulin pump therapy. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial involving 95 patients with type 1 diabetes, recruited from December 2009 to January 2012 in Australia. INTERVENTIONS: Patients were randomized to insulin pump only or automated insulin suspension for 6 months. MAIN OUTCOMES AND MEASURES: The primary outcome was the combined incidence of severe (hypoglycemic seizure or coma) and moderate hypoglycemia (an event requiring assistance for treatment). In a subgroup, counterregulatory hormone responses to hypoglycemia were assessed using the hypoglycemic clamp technique. RESULTS: Of the 95 patients randomized, 49 were assigned to the standard-pump (pump-only) therapy and 46 to the low-glucose suspension group. The mean (SD) age was 18.6 (11.8) years; duration of diabetes, 11.0 (8.9) years; and duration of pump therapy, 4.1 (3.4) years. The baseline rate of severe and moderate hypoglycemic events in the pump-only group was 20.7 vs 129.6 events per 100 patient months in the low-glucose suspension group. After 6 months of treatment, the event rates decreased from 28 to 16 in the pump-only group vs 175 to 35 in the low-glucose suspension group. The adjusted incidence rate per 100 patient-months was 34.2 (95% CI, 22.0-53.3) for the pump-only group vs 9.5 (95% CI, 5.2-17.4) for the low-glucose suspension group. The incidence rate ratio was 3.6 (95% CI, 1.7-7.5; P <.001). There was no change in glycated hemoglobin in either group: mean, 7.4 (95% CI, 7.2-7.6) to 7.4 (95% CI, 7.2-7.7) in the pump-only group vs mean, 7.6 (95%, CI, 7.4-7.9) to 7.5 (95% CI, 7.3-7.7) in the low-glucose suspension group. Counterregulatory hormone responses to hypoglycemia were not changed. There were no episodes of diabetic ketoacidosis or hyperglycemia with ketosis. CONCLUSIONS AND RELEVANCE: Sensor-augmented pump therapy with automated insulin suspension reduced the combined rate of severe and moderate hypoglycemia in patients with type 1 diabetes. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12610000024044.
Key Findings
1
Adjusted incidence rate per 100 patient-months was 9.5 (95% CI, 5.2–17.4) for the low-glucose suspension group versus 34.2 (95% CI, 22.0–53.3) for the pump-only group (incidence rate ratio 3.6; P <.001).
2
Counterregulatory hormone responses to hypoglycemia were not changed, and no episodes of diabetic ketoacidosis or hyperglycemia with ketosis occurred.
3
Event rates decreased more substantially in the low-glucose suspension group (from 175 to 35 per 100 patient-months) than in the pump-only group (from 28 to 16) over 6 months.
4
Sensor-augmented insulin pump therapy with automated low-glucose insulin suspension reduced the combined incidence of severe and moderate hypoglycemia compared with standard pump therapy.
5
There was no change in glycated hemoglobin (HbA1c) in either group over the 6-month study period.
Research Object
Sensor-augmented insulin pump therapy with automated low-glucose insulin suspension in patients with type 1 diabetes
Research Subject
Incidence of severe and moderate hypoglycemia (combined rate) and related clinical outcomes (glycated hemoglobin, counterregulatory hormone responses, ketoacidosis) comparing sensor-augmented pump with automated insulin suspension versus standard insulin pump therapy
Publication Details
Publication Date
2013-09-24
Journal
Publisher
ISSN
Cited by
412
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by5
Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes2017
Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study2017
Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions2022
Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes2015
Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review2019